Search

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

- Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.1 - In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules, one week after receiving

Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

About Us

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario

Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba 

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner

Simple and straight to the source: tips for ileitis control

Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease

Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet

Innovative health projects impact thousands of Indigenous Peoples in Canada

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden

Effective management practices for parasite control in cattle

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Protecting Animals and Humans

Everything we do is about improving the health and well-being of humans and animals.

A versatile solution for PCV2 and PRRS protection

Salmonella in pigs, pork and people

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults

Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

About Us

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention

Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario

Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba

Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner

Simple and straight to the source: tips for ileitis control

Health Canada approves NexGard® and NexGard Spectra™ for the reduction of Lyme disease

Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet

Innovative health projects impact thousands of Indigenous Peoples in Canada

OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

Effective management practices for parasite control in cattle

Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba

Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis

Saskatchewan Health Research Foundation and Boehringer Ingelheim Canada Partner to Improve Chronic Diseases Care in Saskatchewan’s Indigenous Communities

Protecting Animals and Humans

A versatile solution for PCV2 and PRRS protection

Salmonella in pigs, pork and people

Health Canada approves first treatment option for generalized pustular psoriasis flares in adults 

Indigenous Peoples living with diabetes is the focus of four new health pilot projects in Ontario, Nunavut, Alberta, and Manitoba 

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction